Symbiot Self-Expanding Design Key To Trial Success; 2004 Launch Planned
This article was originally published in The Gray Sheet
Executive Summary
Self-expanding ePTFE-covered stent grafts are more effective in treating stenotic saphenous vein grafts (SVGs) than comparable balloon-expandable covered stent grafts, Eberhard Grube, MD, University of Bonn, Germany, asserts
You may also be interested in...
Boston Scientific Symbiot
ePTFE polymer-covered nitinol stent gains investigational device exemption clearance for 700-patient, randomized Symbiot III pivotal trial to treat saphenous vein graft disease...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.